AECOS (American-European Congress of Ophthalmic Surgery)
RevitalVision’s CEO, Yair Yahav, participated in the 2024 AECOS innovation forum, which featured eight top industry innovations. The forum was moderated by Mr. William Link, PhD.
2024 AAPOS annual meeting- Nystagmus study for Oral Presentation
Congratulations to Dr. Sigal Zmujack-Yehiam and her team at the ophthalmology department in the Shamir Medical Center, on the acceptance of their Nystagmus study for Oral Presentation at the prestigious 2024 AAPOS annual meeting.
This prospective open-label randomized controlled clinical study evaluated the efficacy of RevitalVision software in patients with congenital nystagmus.
The results demonstrate significant improvement in functional vision and life quality.
AAPOS 23 annual meeting- presenting poster with mid term study results
During the 48th annual meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS 23), Dr. Sigal Zmujack’s presented the mid-term results of two new controlled randomized studies evaluating RevitalVision’s efficacy in improving vision in nystagmus and amblyopia patients aged 9-55, which both showed significant anti-suppression effects.Download the poster
Narayana Nethralaya Eye Foundation – What & how does my child see Conference
RevitalVision CEO Yair Yahav was a guest speaker at the Narayana Nethralaya Eye Foundation symposium on Amblyopia, Binocular Vision, Cortical Visual Impairment, and Low Vision.
He presented a scientific & clinical review on Optimizing Cortical Visual Functions with RevitalVision.
A new published study on RevitalVision treatment
This independent study, which was published in Vision Development and Rehabilitation: COVD’s Digital Journal, evaluated the efficacy of RevitalVision’s perceptual-based vision training program, in improving visual acuity in adult amblyopic individuals beyond occlusion.Read the full publication (p.260)
Margalit Startup City Haifa- Digital Health Accelerator
We are proud to have been selected as one of the companies to participate in Margalit Startup City’s digital health accelerator in Haifa.Read more
Ophthalmology Innovation Source Summit (OIS)
Our CEO Yair Yahave presented at the OIS Israel (Ophthalmology Innovation Source Summit) during the MIXiii Health-Tech.IL conference between 9-10 November at the ICC in Jerusalem.
Presenting at the ACADEMY 2022 SAN DIEGOThe American Academy of Optometry’s annual meeting
RevitalVision at EPOS 2022 Munich47th Meeting of European Paediatric Ophthalmological Society
Israel: A beacon of light helping with sight
This special feature article in GeekTime profiles innovative optics treatments and technologies from leading start-ups.To the full article
RevitalVision will present at ESCRS2022
We will be presenting at the 40th annual congress of The European Society for Cataract and Refractive Surgery (ESCRS) in Milan, Italy, from 16-19 September 2022.
For more information on the ESCRS congress
RevitalVision at the AAO 2022 mid year press relase
New randomized controlled trial on RevitalVision
Effects of Perceptual Learning on Deprivation Amblyopia in Children with Limbal Dermoid: A Randomized Controlled Trial
The study compared 2 groups of children with amblyopia after corneal transplant : One group received standard patching therapy and the second group received patching + RevitalVision.
The group that underwent RevitalVision therapy experienced statistically significant improvement in vision.Read the full study
RevitalVision will present at the AAPOS 2022 – Arizona
2022 Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS), on March 23-27, 2022.
RevitalVision at HIMSS 22
This year, the Israel Export Institute together with the Foreign Trade Administration – Ministry of Economy & Industry will present 18Israeli Digital Health companies. And we are proud to be amongst these innovative companies
RevitalVision on The Ophthalmologist
Yair Yahav, CEO and founder of RevitalVision, was interviewed in The Ophthalmologist about how we improve vision in adult amblyopia
RevitalVision received reimbursement code in the USA
RevitalVision is a standalone therapeutic vision training software, the only FDA-approved product for market, and clinically proven to improve vision in adult amblyopia (age 9-plus), received a unique Current Procedural Terminology (CPT) reimbursement code from the American Medical Association (AMA).
3-6 November 2021
American Academy of Optometry Annual Meeting
We’re excited to be one of the exhibitors at the American Academy of Optometry Annual Meeting – which will be taking place in Boston. Visit us in the exhibit hall at booth #843
12-15 November 2021
American Academy of Ophthalmology Annual Meeting
Come meet our experts at the AAO annual meeting, taking place in New Orleans this November
RevitalVision participates at MedinIsraelRevitalVision in MedinIsrael exhibition
RevitalVision New Product Release
We are happy to announce the release of our new web vision training software application with RevitalVision new branding. This advance software, which is designed to improve vision by improving the brain visual processing, is easier to use and provides better patient feedback.
WSPOS – World Wide Webinar on Amblyopia – Sponsored by REVITALVISIONWorld Society of Pediatric Ophthalmology and Strabismus
21-24 April 2021
REVITALVISION will participate at the upcoming 41st ESA (EUROPEAN STRABISMOLOGICAL ASSOCIATION)
Meeting in PARIS 21th /24th April 2021Link to article
A New Adult Amblyopia study presented at AIOS 2020 (All India Ophthalmology Society)
meeting 2020 confirming again the efficacy of RevitalVision in improving vision in adult amblyopiaDownload ppt
REVITALVISION will participate at the upcoming AAOPT (AMERICAN ACADEMY of OOPTOMETRY)
Meeting in Nashville, TN, USA 7-10 OctoberLink to article
Tel Aviv Medical Center is recruiting Age related Macular Degeneration patients for a REVITALVISION clinical study
A Proof-of-Concept, Prospective, Open label, Randomized Clinical Study Evaluating RevitalVision® Therapy for Improving Best Corrected Visual Acuity (BCVA) and Contrast Sensitivity Function (CSF) in Patients Suffering from stabler Age related Macular Degeneration (AMD)